RAC 0.67% $1.49 race oncology ltd

1993: 5 of a total of 7 (72%) patients achieved total eradication of their cancer (R/R AML), page-18

  1. 11,249 Posts.
    lightbulb Created with Sketch. 29637
    I've charted the available Phase II trials data for Bisantrene (RAC) and PTX-200 (PTX).

    Sources:
    1. Marty M, et al. Cancer Treat Rep. 1985;69:703-705. 2. Marty M, et al. Fourth International Symposium on
    2. Therapy of Acute Leukemia. Series Bisantrene: an anthracycline derivative active in ANLL: Phase 2 Study. Rome, Italy; 1987. Abstr. 598.
    3. Leblanc T, et al. Med Pediatr Oncol. 1994;22:119-124.
    4. Tosi P, et al. Haematologica. 1989;74:555-558.
    5. Bezwoda WR, Seymour L. Bone Marrow Transplant. 1989;4(suppl 3): 65.
    6. Spadea A, et al. Leuk Lymphoma 1993;9:217-220.
    7. https://www.asx.com.au/asxpdf/20191127/pdf/44c022j20vm3j9.pdf



    Screen Shot 2019-11-28 at 9.41.20 pm.png
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.